ES2119934T3 - Lys-plasminogeno en la prevencion y tratamiento de la isquemia y las lesiones de reperfusion. - Google Patents

Lys-plasminogeno en la prevencion y tratamiento de la isquemia y las lesiones de reperfusion.

Info

Publication number
ES2119934T3
ES2119934T3 ES94110267T ES94110267T ES2119934T3 ES 2119934 T3 ES2119934 T3 ES 2119934T3 ES 94110267 T ES94110267 T ES 94110267T ES 94110267 T ES94110267 T ES 94110267T ES 2119934 T3 ES2119934 T3 ES 2119934T3
Authority
ES
Spain
Prior art keywords
plasminogen
lys
ischemia
treatment
reperfusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94110267T
Other languages
English (en)
Inventor
Johann Dr Eibl
Ludwig Prof Pichler
Hans-Peter Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2119934T3 publication Critical patent/ES2119934T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Electrotherapy Devices (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • External Artificial Organs (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

UN TRATAMIENTO PARA LA ISQUEMIA Y SU SECUELA, LAS LESIONES POR REPERFUSION QUE CONSISTE EN ADMINISTRAR PLASMINA Y PROTEINAS FORMADORAS DE PLASMINA, INCLUIDO EL LYS STANCIAS SIMILARES. SE HA DESCUBIERTO QUE EL LYS OS POR ESTADOS ISQUEMICOS. LA ADMINISTRACION DEL LYS OGEN SE PUEDE UTILIZAR PARA EL TRATAMIENTO DE SUJETOS DURANTE EL TIEMPO DE REPERFUSION Y UNA VEZ HAYA TENIDO LUGAR LA REPERFUSION. EL LYS CON TERAPIAS DE LISIS DE COAGULOS, TALES COMO AQUELLAS EN LAS QUE SE UTILIZA UN ACTIVADOR DE PLASMINOGENES EN LOS TEJIDOS Y SIMILARES.
ES94110267T 1993-07-02 1994-07-01 Lys-plasminogeno en la prevencion y tratamiento de la isquemia y las lesiones de reperfusion. Expired - Lifetime ES2119934T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8803393A 1993-07-02 1993-07-02

Publications (1)

Publication Number Publication Date
ES2119934T3 true ES2119934T3 (es) 1998-10-16

Family

ID=22208925

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94110267T Expired - Lifetime ES2119934T3 (es) 1993-07-02 1994-07-01 Lys-plasminogeno en la prevencion y tratamiento de la isquemia y las lesiones de reperfusion.

Country Status (19)

Country Link
US (2) US5520912A (es)
EP (1) EP0631786B1 (es)
JP (1) JP2784146B2 (es)
AT (2) ATE167400T1 (es)
AU (1) AU680492B2 (es)
CA (1) CA2127199C (es)
CZ (1) CZ283352B6 (es)
DE (1) DE69411084T2 (es)
DK (1) DK0631786T3 (es)
ES (1) ES2119934T3 (es)
GR (1) GR3027778T3 (es)
HR (1) HRP940381B1 (es)
HU (1) HU217961B (es)
NO (1) NO942367L (es)
PL (1) PL304061A1 (es)
RU (1) RU2153353C2 (es)
SI (1) SI0631786T1 (es)
SK (1) SK281472B6 (es)
ZA (1) ZA944522B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4411143C2 (de) * 1994-03-30 1996-08-01 Immuno Ag Thrombosemittel
ATE349226T1 (de) * 1998-09-29 2007-01-15 Leuven Res & Dev Vzw Verwendung von verbindungen die alpha2- antiplasmin in vivo reduzieren zur herstellung einer zusammensetzung zur behandlung ischämischer schlaganfälle
EP1062953A1 (en) * 1999-06-22 2000-12-27 Leuven Research & Development vzw Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
WO2000041714A1 (en) * 1999-01-19 2000-07-20 Bristol-Myers Squibb Company Method for determining care and prevention pathways for clinical management of wounds
US7184963B1 (en) 1999-01-19 2007-02-27 Bristol-Myers Squibb Company Method for determining care and prevention pathways for clinical management of wounds
AU3173301A (en) * 2000-02-11 2001-08-20 European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
US20050124036A1 (en) * 2002-02-06 2005-06-09 Rudy Susilo Method for producing recombinant proteins in micro-organisms
AU2003252039A1 (en) * 2002-07-23 2004-02-09 Vegenics Limited Methods and compositions for activating or inhibiting vegf-d and vegf-c
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
RU2341256C1 (ru) * 2007-03-26 2008-12-20 Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава Способ профилактики реперфузионных осложнений у пациентов, оперированных по поводу хронической ишемии нижних конечностей
RU2411911C1 (ru) * 2009-07-02 2011-02-20 Клиника государственного образовательного учреждения высшего профессионального образования "Челябинская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию"(Клиника ГОУ ВПО ЧелГМА Роздрава) Способ прогнозирования характера течения реперфузионного синдрома после поэтапного хирургического лечения сонных артерий у пациентов с симптомными бикаротидными стенозами
KR20120050442A (ko) 2009-07-10 2012-05-18 쓰롬보제닉스 엔.브이. 플라스미노겐 및 플라스민의 변이체
US20120189609A1 (en) 2009-08-28 2012-07-26 Thrombogenics Nv Improvement to trabeculectomy
EP2661493B1 (en) 2011-01-05 2016-03-30 ThromboGenics N.V. Plasminogen and plasmin variants
JP6000353B2 (ja) 2011-08-12 2016-09-28 スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ プラスミノーゲンおよびプラスミンの変異体
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
TWI677348B (zh) * 2016-12-15 2019-11-21 大陸商深圳瑞健生命科學研究院有限公司 一種改善心臟病變的方法
WO2018107686A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种治疗动脉粥样硬化及其并发症的方法
JP7168990B2 (ja) 2016-12-15 2022-11-10 タレンゲン インターナショナル リミテッド 肥満症を予防および治療するための方法および薬物
TWI868051B (zh) * 2017-06-23 2025-01-01 美商波麥堤克生物治療股份有限公司 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
RU2729788C2 (ru) * 2018-09-04 2020-08-12 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Пущинский научный центр биологических исследований Российской академии наук" Средство, его применение и способ повышения устойчивости организма млекопитающих к ишемически-реперфузионному поражению тонкого кишечника
AU2020212404B2 (en) 2019-01-24 2025-11-27 Previpharma Consulting Gmbh Plasminogen for treating and preventing microthrombosis
SG11202110554YA (en) * 2019-04-12 2021-10-28 Uglk Science Ab Method and apparatus for reconditioning kidneys
SG11202110553PA (en) * 2019-04-12 2021-10-28 Uglx Res Ab Method and apparatus for reconditioning organs
CN114642722A (zh) * 2020-12-18 2022-06-21 四川大学华西医院 纤溶酶原用于制备促进血管新生的药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0028489B1 (en) * 1979-11-05 1983-10-05 Beecham Group Plc Enzyme derivatives, and their preparation
DE3715662A1 (de) * 1986-05-12 1987-11-19 Wellcome Found Neue pharmazeutische anwendung
JP2764264B2 (ja) * 1987-10-01 1998-06-11 株式会社ミドリ十字 線溶活性増強剤
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
AT390801B (de) * 1988-07-28 1990-07-10 Immuno Ag Verfahren zur herstellung von lys-plasminogen
US5358936A (en) * 1990-08-03 1994-10-25 Paul Gordon Anionic furanose derivatives, methods of making and using the same
AT402367B (de) * 1990-10-11 1997-04-25 Immuno Ag Pharmazeutische zubereitung auf basis von lys-plasminogen

Also Published As

Publication number Publication date
AT407706B (de) 2001-05-25
RU94022754A (ru) 1996-08-10
ZA944522B (en) 1995-02-23
NO942367L (no) 1995-01-03
HRP940381B1 (en) 1999-06-30
HU9401983D0 (en) 1994-09-28
US5597800A (en) 1997-01-28
CZ161394A3 (en) 1995-01-18
JPH07145076A (ja) 1995-06-06
ATE167400T1 (de) 1998-07-15
SI0631786T1 (en) 1998-10-31
SK281472B6 (sk) 2001-04-09
HUT67225A (en) 1995-03-28
SK79894A3 (en) 1995-05-10
US5520912A (en) 1996-05-28
GR3027778T3 (en) 1998-11-30
NO942367D0 (es) 1994-06-21
CZ283352B6 (cs) 1998-03-18
CA2127199C (en) 2000-11-28
DK0631786T3 (da) 1999-04-06
PL304061A1 (en) 1995-01-09
AU6485494A (en) 1995-01-12
ATA131094A (de) 2000-10-15
HRP940381A2 (en) 1997-04-30
JP2784146B2 (ja) 1998-08-06
RU2153353C2 (ru) 2000-07-27
DE69411084D1 (de) 1998-07-23
AU680492B2 (en) 1997-07-31
CA2127199A1 (en) 1995-01-03
EP0631786B1 (en) 1998-06-17
HU217961B (hu) 2000-05-28
EP0631786A1 (en) 1995-01-04
DE69411084T2 (de) 1998-12-03

Similar Documents

Publication Publication Date Title
ES2119934T3 (es) Lys-plasminogeno en la prevencion y tratamiento de la isquemia y las lesiones de reperfusion.
NO885109D0 (no) FremgangsmŸte og middel for Ÿ forhindre blodpropp.
DK0759747T3 (da) Transdermal indretning til administration gennem de-epitheliseret hud
ES2182899T3 (es) Formulacion farmaceutica para la administracion subcutanea, intramuscular o intradermica de factor viii.
ATE233099T1 (de) Eine formulierung des gerinnungsfaktors viii
WO2002029087A3 (en) Use of lymphangiogenic agents to treat lymphatic disorders
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
ES2183805T3 (es) Procedimiento de preparacion de un medicamento trombolitico.
DE69832176D1 (de) Arzneimittel gegen diabetes-komplikationen
ES2085326T3 (es) Activador de plasminogeno salivar del murcielago vampiro vpa-alfa1.
DK0604995T3 (da) Hydroxyamin-N-acylderivater, som har radikalfjernende aktivitet og kan anvendes ved akutte og kroniske patologier forbundet
KR900701309A (ko) 액체 질소 및 재조합 DNA사람 α인터페론을 혼용하여 생식기우종을 치료하는 방법
ES2033295T3 (es) Un metodo para preparar un activador de plasminogeno.
DK0381640T3 (da) Thrombolytiske præparater
CA2527572A1 (en) Formulations containing thrombolytic agents for rectal administration
NO960866D0 (no) Fremgangsmåte til behandling av leversykdom og lignende indikasjoner med vasodilaterende midler
Zimmermann et al. Urokinase therapy of deep vein thrombosis of the lower limb

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 631786

Country of ref document: ES